We’ve made some changes to improve our site’s navigation.

Learn More

AstraZeneca PLCAZN:LSE

3,250.5
4.00 / 0.12%
1.59m
21.15%
0.3259
Close in GBXToday's changeShares traded1 year changeBeta
As of Jun 18 2013 16:58 BST.Data delayed by at least 15 minutes.

Search 526 articles on AstraZeneca PLC

Clear filters
Search

Jun 17 2013 00:52 BST
'Shareholder spring' reaches small UK businesses
The shareholder spring has reached small companies, with rising numbers of investors opposing their executive pay plans, according to KPMG, the financial services firm. This year, 20 per cent of small caps have failed to win 80 per cent of support for their remuneration reports, the report says. This comparesBy Kate Burgess
Jun 13 2013 00:07 BST
Biotechnology
It can trace its roots to Europe's apothecaries in the Middle Ages and the 19th-century dye and bulk chemical producers of Germany's Ruhr valley, but the pharmaceutical sector has become a significant global industry in its own right. Academic researchers and doctors make most breakthroughs, but the sector has supportedOverview by Andrew Jack
Jun 10 2013 17:53 BST
Elan boosted by talk of counterbid
Gains for a number of drugmakers and engineering companies helped ensure the fall on the pan-European index was kept to a minimum on Monday, as heavy losses were seen in some of Europe's periphery stock markets. Bid interest in the pharmaceuticals sector was the main talking point as London-listed AstraZenecaBy Neil Dennis
Jun 10 2013 12:35 BST
Lombard: AstraZeneca looks to pass 'Go' with triple therapy play
If respiratory medicine were a game of Monopoly, AstraZeneca would be a player who has just completed a set of three higher value properties and plans to start building houses. It has agreed to buy Pearl Therapeutics partly because the US group has a drug intended to dry up lungBy Jonathan Guthrie
Jun 10 2013 12:28 BST
AstraZeneca: the long slog
Little can be said with certainty about AstraZeneca except that its rebuilding will be expensive and long. Monday's announcement of its purchase of Pearl Therapeutics for as much as $1.15bn illustrates the first point nicely. Privately-held Pearl has two potential treatments for respiratory diseases in development, including one in late-stage
Jun 10 2013 08:43 BST
AstraZeneca buys inhaled drug specialist
AstraZeneca has acted to bolster its dwindling drug pipeline with the acquisition a Californian-based respiratory medication specialist in a deal worth as much as $1.15bn. The Anglo-Swedish pharmaceuticals group on Monday said it had agreed to pay an initial $560m for Pearl Therapeutics, a privately owned developer of inhaled treatmentsBy Mark Wembridge
Jun 04 2013 22:32 BST
HSBC cases suggest it is better to be hung for a lamb
Congratulations, HSBC. A US watchdog, prompted by a burning love of justice, or perhaps just burning political ambition, is having a go at you. The good news is that alleged offence is the kind that banks habitually get in trouble over. And for HSBC that marks a kind of moralBy Jonathan Guthrie
Jun 04 2013 17:24 BST
Arthritis drug setback for new AstraZeneca chief Pascal Soriot
AstraZeneca has abandoned the development of a late-stage experimental treatment for rheumatoid arthritis, in a blow to the efforts of its new chief executive to generate new sources of revenue. The Anglo-Swedish pharmaceutical group said that after a review of the clinical results it was writing off $140m in researchBy Andrew Jack
May 31 2013 14:32 BST
Letter from Lex: great heights
Sixty years after Edmund Hillary and Tenzing Norgay conquered Mount Everest, some companies were also trying to scale great heights this week. Much of the news involved M&A deals, especially in the pharma and telecoms sectors. In the first, Valeant bought Bausch & Lomb for $8.7bn after losing the race
May 28 2013 20:07 BST
GSK receives boost from Deutsche as FTSE 100 sports strong rise
GlaxoSmithKline was a riser on Tuesday as the FTSE 100 registered its biggest daily gain in a month. The drugmaker hit an 11-year high on the back of an upgrade from Deutsche Bank, which argued that earnings expectations had reached a trough. "We are at the juncture where either GSK'sBy Bryce Elder
More AstraZeneca PLC headlines

RNS Company announcements

Jun 12 2013 16:00 BST
Director/PDMR Shareholding
Jun 12 2013 16:00 BST
Director/PDMR Shareholding
Jun 12 2013 16:00 BST
Director/PDMR Shareholding
Jun 10 2013 08:00 BST
To Acquire Pearl Therapeutics
Jun 04 2013 08:00 BST
Top-line results from Phase III Oskira trials

Business Wire
press releases

Jun 14 2013 14:00 BST
AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®
Jun 12 2013 18:11 BST
AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies
Jun 11 2013 16:02 BST
SumTotal Customers and Industry Leaders Kick off Talent Expansion™ Tour 2013
Jun 04 2013 14:54 BST
Customers Vote SumTotal Finalist in Four Best of Elearning! 2013 Awards
Jun 04 2013 14:03 BST
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca’s Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy

Reuters News Service company announcements are delayed by up to one hour.

© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.



VIDEOS